跳至主要内容
临床试验/NCT05707897
NCT05707897已完成1 期

A Study to Assess the Food Effect of TS-142 in Healthy Subjects

Taisho Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2023年2月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Plasma concentration

研究概览

简要总结

This is a study to assess the food effect of TS-142 preliminary market formulation tablet in healthy subjects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Japanese male who are aged 18 years or older but less than 40 years at the time of informed consent
  • Body Mass Index (BMI) of 18.5 or more and less than 25.0 at the screening test
  • Subjects who are judged by the investigators as an eligible for the clinical trial participation based on the screening tests and the tests conducted at treatment period
  • Other protocol defined inclusion criteria could apply.

排除标准

  • Subjects who are judged to have any disease by the principal investigator or sub-investigator and are not considered healthy
  • Subjects who have any unsuitable medical history for participation in this study, including respiratory, cardiovascular, gastrointestinal, hepatic, renal, urological, endocrinological, metabolic, hematologic, immunologic, dermatological, neurological, or psychiatric diseases
  • Subjects who have any medical histories including sleep-associated symptoms, narcolepsy-like symptoms, suicidal ideation, or suicidal attempts
  • Other protocol defined exclusion criteria could apply.

研究组 & 干预措施

Fed condition

Experimental

Period in which subjects receive a single oral dose of TS-142 tablet in fed condition.

干预措施: TS-142 10 mg (Drug)

Fasted condition

Experimental

Period in which subjects receive a single oral dose of TS-142 tablet in fasted condition.

干预措施: TS-142 10 mg (Drug)

结局指标

主要结局

Plasma concentration

时间窗: Predose and up to 24 hours postdose

Plasma concentration of unchanged form and its metabolite

Pharmacokinetic parameters

时间窗: Predose and up to 24 hours postdose

Apparent total body clearance of unchanged form (CL/F)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验